Skip to main content

Table 2 Lyme disease history and self-reported cognitive symptoms

From: Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET

Lyme disease history

Patients with persistent symptoms following treated Lyme disease (N = 12)

Medical record-confirmed Lyme disease presentation

 CDC confirmed: physician-documented erythema migrans rasha

6 (50.0%)

 CDC probable: subjective symptoms/(+) serologyb

6 (50.0%)

PTLDS symptom duration ≥ 6 months at study visit

8 (66.7%)

Self-reported cognitive symptoms

 Memory change, moderate or severe

7 (58.3%)

 Difficulty finding words, moderate or severe

7 (58.3%)

 Difficulty focusing or concentrating, moderate or severe

9 (75.0%)

 Cognitive symptoms,c any

12 (100.0%)

Neurocognitive test T-scores

 Trail making test [28], part A

52.50 ± 18.53 (17.00, 80.00)

 Trail making test, part B

46.67 ± 14.25 (19.00, 68.00)

 HVLT [29] total recall

48.50 ± 11.87 (32.00, 64.00)

 HVLT delayed recall

47.92 ± 11.41 (25.00, 59.00)

 HVLT retention

51.00 ± 9.36 (26.00, 61.00)

 HVLT recognition discrimination

46.33 ± 12.52 (20.00, 58.00)

 WAIS-IV [30] digit span

49.25 ± 8.28 (37.00, 67.00)

 WAIS-IV coding

52.83 ± 7.72 (40.00, 70.00)

 ACT [31] 9d

54.10 ± 7.26 (37.00, 62.00)

 ACT 18d

54.50 ± 8.83 (38.00, 69.00)

 ACT 36d

55.60 ± 9.92 (37.00, 69.00)

Standardized symptom questionnaires

 Fatigue Severity Scale Total Score

50.42 ± 10.33 (25.00, 63.00)

 Pittsburgh Sleep Quality Index Total Score

11.40 ± 4.67 (4.00, 19.00)

 Short-Form McGill Pain Questionnaire Total Score

11.67 ± 6.84 (0.00, 24.00)

 Beck Depression Inventory II Total Score

14.18 ± 7.10 (3.00, 24.00)

 SF-36 Physical Component Score

34.91 ± 8.24 (20.21, 50.06)

 SF-36 Mental Component Score

38.60 ± 11.95 (20.86, 59.47)

  1. ACT Auditory Consonant Trigrams, HVLT Hopkins Verbal Learning Test, SF-36 Short-Form Health Survey, WAIS-IV The Wechsler Adult Intelligence Scale, 4th edition
  2. Data from normally distributed continuous variables are presented as mean ± standard deviation (range) and from continuous variables not normally distributed as median [25th percentile, 75th percentile] (range). Data from categorical variables are presented as count (%)
  3. aOne patient with erythema migrans rash and Bell’s Palsy
  4. bViral-like illness/(+) ELISA/WB, or non-acute patient reported symptoms/(+) IgG-WB
  5. cAt least one of the following present during the past 2 weeks: (1) difficulty finding words, (2) difficulty focusing or concentrating, and (3) trouble with memory
  6. dMissing data from 2 of the 12 patients (16.7%) due to the later addition of the ACT to the study protocol
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094